Do Peptide Nasal Sprays Work? Intranasal Delivery of Research Peptides

Do Peptide Nasal Sprays Work? Intranasal Delivery of Research Peptides

The nasal route is not a shortcut around pharmacology. It is a real absorption surface with real limits, and those limits are mostly set by one number: how big the peptide is. This research-use-only reference covers what crosses the nasal epithelium, what the approved intranasal peptide drugs tell us about realistic bioavailability, and which compounds in a research catalogue sit inside the size range where the route has any published support.

Michael Phelps

Founder & Peptide Research Specialist, PrymaLab

Research reference · Last updated August 6, 2026 · ~11 min read

Why the Intranasal Route Gets Studied

Peptides are difficult to deliver by any route other than injection. They are large, water-soluble, and enzymatically fragile, which rules out ordinary oral dosing for most of them. The nasal cavity is attractive because it sidesteps two of those problems at once: the epithelium is thin and heavily vascularised, and anything absorbed there enters systemic circulation without first passing through the liver.^[1]

The surface available is larger than it looks. Turbinate folding gives an adult nasal cavity on the order of 150 square centimetres, and blood flow per gram of tissue there is high relative to most mucosal surfaces.^[1] That combination is why the route works for small molecules and why formulation scientists keep returning to it for peptides.

The honest counterweight is that a good absorption surface does not make a molecule absorbable. Everything below is about which molecules the surface actually admits.

What Actually Crosses the Nasal Epithelium

Two routes matter. Transcellular transport moves lipophilic molecules through the cell membranes themselves, and it handles small lipid-soluble compounds well. Paracellular transport squeezes hydrophilic molecules between adjacent cells, through the tight junctions.^[1]

Peptides are hydrophilic. They take the paracellular route, and tight junctions are physically narrow. That is the whole reason molecular weight dominates this topic. A tripeptide and a 43-residue protein are not making the same journey with different efficiency. They are effectively facing different doors, and only one of them fits.

Molecular Size, and Where Each Compound Sits

Passive paracellular permeation for hydrophilic compounds declines steeply somewhere around 1 kDa.^[1] That figure is a working rule rather than a wall, and there is a well-known exception discussed further below. Here is roughly where common research peptides fall.

A few notes that matter more than the table itself.

The Khavinson bioregulators are the smallest things here by a wide margin. Vilon is a dipeptide at roughly 275 Da. Thymogen is 333 Da. If molecular size were the only variable, these would be the most plausible intranasal candidates in the entire catalogue, and it is worth noting that the bioregulator literature is also the thinnest and most geographically concentrated. Size and evidence quality are independent problems.

"TB-500" is ambiguous and the ambiguity is a size problem. Some material sold under that name is the short thymosin beta-4 fragment 17 to 23, which is under 900 Da. Some is full-length thymosin beta-4, 43 residues and close to 4,963 Da. Those two are on opposite sides of the permeation question. Anyone comparing intranasal preparations should establish which one they have. See the TB-500 spray reference material listing and its certificate of analysis for the specific sequence supplied.

IGF-1 LR3 is an outlier. At roughly 9,111 Da it is an order of magnitude past the passive permeation range. Any nasal delivery of a molecule that size would depend on formulation enhancement, on paracellular junction modulation, or on routes other than simple diffusion, and published data specific to that compound intranasally is scarce.

The Nose-to-Brain Question

The most cited reason for interest in intranasal peptides is not systemic absorption at all. It is the possibility of direct transport from the nasal cavity to the central nervous system along the olfactory and trigeminal nerves, bypassing the blood-brain barrier entirely.^[2][3]

The anatomy is real. Olfactory sensory neurons project through the cribriform plate directly into the olfactory bulb, and trigeminal branches innervate the nasal mucosa and reach the brainstem. Both provide a physical path that does not require crossing the blood-brain barrier.^[3]

The caveats are substantial. The olfactory region is a small fraction of the total nasal surface in humans, on the order of 10 square centimetres in the upper cavity, and ordinary spray devices deposit most of their volume on the lower respiratory epithelium rather than up there.^[2] The fraction of an applied dose that reaches the CNS by this route in humans has been contested for two decades, and the strongest evidence remains in rodents, whose nasal anatomy allocates far more relative area to olfactory epithelium than ours does.

Intranasal oxytocin is the best-studied case and remains genuinely debated, with a large literature and persistent methodological argument about whether measured central effects reflect direct nose-to-brain transport, systemic absorption with subsequent CNS entry, or peripheral effects interpreted centrally.^[4] That a compound this small and this heavily studied is still contested says something useful about how much weight to place on the pathway for anything larger or less studied.

What Limits Absorption

Three mechanisms cap how much of an applied peptide gets anywhere.

Mucociliary clearance. The nasal mucosa continuously moves its mucus layer toward the nasopharynx, and deposited material goes with it. Clearance half-time in healthy adults is commonly reported near 15 to 20 minutes.^[1] That sets a hard ceiling on residence time, which is why mucoadhesive formulations exist.

Enzymatic degradation. Nasal mucosa contains aminopeptidases and other proteases. A peptide is being cleaved while it is trying to cross, and shorter sequences with unprotected termini are the most exposed. N-acetylation and amidation, which appear on several research peptides, are partly about this.

Tight junction restriction. Covered above. This is the dominant term for anything above about 1 kDa.

Formulation science has answers to all three: permeation enhancers, chitosan and other mucoadhesive polymers, cyclodextrins, enzyme inhibitors, and particle engineering to target the upper cavity.^[1] Whether any given research preparation uses any of them is usually not disclosed, and a plain aqueous solution in a spray bottle uses none of them.

What the Approved Intranasal Peptides Tell Us

The most useful evidence in this whole area comes from peptides that went through formal development. Several have approved intranasal formulations, which means their bioavailability was measured properly rather than assumed.

Two things stand out. First, four of the five sit between roughly 1,000 and 1,350 Da, which is where the size rule predicts marginal but workable permeation. Second, salmon calcitonin at 3,432 Da breaks the rule, and it does so at about 3 percent bioavailability. That is the honest shape of the exception: much larger peptides can be delivered nasally, at a delivered fraction low enough that it only makes sense when the compound is potent and the formulation is engineered for it.

There is also an instructive negative result. PT-141 (bremelanotide) was originally developed as an intranasal product. Development moved to subcutaneous administration after blood pressure increases were observed in intranasal trials.^[5] The nasal route was not abandoned because the peptide failed to absorb. It was abandoned because it absorbed in a way that produced an unacceptable effect. Anyone reasoning about PT-141 intranasal reference material should know that history.

Intranasal Compared With Injection

No published head-to-head pharmacokinetic comparison exists for the research peptides in this category. What exists is the general pattern from developed drugs, and that pattern is consistent: intranasal bioavailability for unmodified peptides lands in the low single digits against subcutaneous or intravenous reference.^[1]

Framed usefully, the nasal route trades delivered fraction for two things. One is avoiding an injection. The other is a possible direct CNS pathway that injection does not offer. Whether either trade is worth making depends entirely on the research question, and neither is a claim that the two routes are equivalent.

Any source stating that a peptide nasal spray delivers comparably to injection should be asked for the study. For most of these compounds there is not one.

Handling and Stability of Solution Reference Material

This section covers laboratory handling of reference material. It is not administration guidance.

Peptides are markedly less stable in solution than as lyophilised powder. Hydrolysis, oxidation of methionine and cysteine residues, deamidation of asparagine and glutamine, and adsorption to container surfaces all proceed faster in aqueous phase. The practical implications for a solution-format reference material are that it is generally held refrigerated and protected from light, that freeze-thaw cycling is avoided, and that a working solution has a shorter useful life than the lyophilised source material.

Specifics vary by sequence, buffer composition, pH and whether a preservative is present, so the storage guidance and certificate of analysis supplied with a particular lot supersede any general rule. At PrymaLab, research peptides are characterised with HPLC and mass spectrometry verification and independent third-party testing.

What Research Has Not Established

For the overwhelming majority of research peptides supplied in spray format, no intranasal bioavailability figure has been published. Not a low one, not a disputed one. None. That absence is the single most important fact in this article and it is the one most often glossed over.

Also unestablished: what fraction of an applied dose reaches the human CNS by the olfactory route for any specific research peptide; whether spray devices used outside formal drug development deposit material where the olfactory pathway could use it; and whether the size rule that works for well-characterised peptides transfers cleanly to modified analogues with acetylation, amidation or non-natural residues.

What is reasonably well established is the mechanism, the anatomy, the clearance kinetics, and the bioavailability range for the handful of peptides that went through formal development. That is a real body of knowledge. It is just narrower than the confidence with which this topic is usually discussed.

Where the individual compounds are covered

This reference is deliberately about the route rather than any single peptide. Compound-specific mechanism references live in the PrymaLab Research Hub, and the spray-format reference materials are listed under peptide nasal sprays.

Frequently Asked Questions

Do peptide nasal sprays work?

It depends almost entirely on the peptide. Several small peptides have approved intranasal formulations, so the route demonstrably works for some sequences. Absorption falls off sharply with molecular size, and for most research peptides no intranasal bioavailability figure has been published at all.

How does intranasal peptide absorption actually happen?

Through roughly 150 cm² of thin, densely vascularised epithelium that drains straight into systemic circulation and skips first-pass liver metabolism. Peptides cross mainly by the paracellular route between cells, which is size-restricted. A separate olfactory and trigeminal pathway may carry some material toward the CNS.

Why does molecular weight matter so much?

Because paracellular transport through tight junctions is physically size-limited. Passive permeation drops steeply above about 1 kDa. Salmon calcitonin at 3,432 Da is the well-known exception, approved intranasally at roughly 3 percent bioavailability.

Are peptide nasal sprays as effective as injections?

No published comparison supports equivalence for research peptides. Measured intranasal bioavailability for developed peptide drugs typically sits in the low single digits against injection.

What limits how much peptide is absorbed nasally?

Mucociliary clearance with a half-time near 15 to 20 minutes, mucosal aminopeptidases that degrade peptides in place, and size restriction at the tight junctions.

Do peptide nasal sprays need to be refrigerated?

Solution-format material is generally held refrigerated and protected from light, with lyophilised material frozen for long-term storage. Specifics vary by sequence and buffer, so follow the storage guidance supplied with the lot.

Is intranasal peptide material approved for human use?

No. These are laboratory reference materials for in-vitro and research use only, not drugs, and not approved by any regulatory authority for human or veterinary use.

References